The combination of irinotecan (Camptosar), epirubicin, and capecitabine (Xeloda) has shown an acceptable toxicity profile. In this open-label phase I study, irinotecan was administered IV at a fixed dose of 250 mg/m2 on day 1 in combination with capecitabine at a fixed dose of 1500 mg/m2 for days 2 to 7 and epirubicin starting at a dose of 40 mg/m2 and escalating by 10 mg/m2 in cohorts of three...

AIM To evaluate the effectiveness of the addition of epirubicin to conventional chemotherapy as a first-line therapy for stage III-IV epithelial ovarian cancer. MATERIALS AND METHODS A total of 132 patients who had undergone primary cytoreductive surgery between January 1998 and March 2003 were enrolled in the study. Twenty-four cases were excluded. Out of the remaining 108 subjects, 35 recei...

4. Ganzina F. 4’Epi-Doxorubicin; A new analogue of Doxorubicin: A preliminary overview of preclinical clinical data. Cancer Treat Rep 1983,10, l-22. 5. Jones WG, Mattsson W. Phase II study of weekly low dose 4’epidoxorubicin in advanced postmenopausal breast cancer. Cancer Treat Rep 1984,60,675-677. 6. Jones WG. Effective palliation of advanced breast cancer with weekly low dose Epirubicin. Eur...

Background: We aimed to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE), a combination of raltitrexed, oxaliplatin, and epirubicin, for unresectable hepatocellular carcinoma (HCC). Methods: We enrolled 163 patients in this single-center, randomized, controlled trial comparing TACE with epirubicin and oxaliplatin (control group; 83 patients) to TACE with ralti...

We recently reported induction ofUGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells. Using the same HepG2 model cell line, the present study assessed the possibility of a similar induction of UGT2B7 by several other cytotoxic drugs. We first demonstr...

BACKGROUND No standard chemotherapy is used as neoadjuvant therapy in triple negative breast cancer (TNBC). This study has compared carboplatin plus paclitaxel with commonly used epirubicin plus paclitaxel as neoadjuvant chemotherapy (NAC) in TNBC. RESULTS 91 patients with a median age of 47 years (PC 47 patients, EP 44 patients) were enrolled. 65% of the patients were premenopausal. While th...

BACKGROUND The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel. PATIENTS AND METHODS We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) wit...

A concise and efficient asymmetric synthesis of ACNO analogues of morphine is reported.

BackgroundDoxorubicin is a cornerstone drug for breast cancer treatment. Epirubicin an effective epimer of doxorubicin with less cardiotoxicity, and pegylated liposomal (PLD), formulation lower toxicity than doxorubicin. We report the interim efficacy safety results from first phase II randomized trial aimed to compare PLD-based epirubicin-based adjuvant chemotherapy stage I-II Her2-negative ca...